Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced esophageal squamous cell cancer that cannot be fully removed by surgery (metastatic or locally advanced unresectable)
- Your cancer has gotten worse after one prior standard treatment line that included a platinum drug and an anti–PD-1 or anti–PD-L1 immune therapy
- You can provide a tumor tissue sample from the past (archival) or a recent sample from clinical practice
- If you had side effects from prior cancer treatment, they must be back to mild level (no more than Grade 1, or about baseline); exceptions include controlled hormone side effects and limited nerve damage (up to Grade 2 neuropathy)
- You should not have tumors directly invading nearby major structures like the aorta or trachea
- You should not have certain major risks or conditions (examples: active inflammatory bowel disease needing immune-suppressing medicine, active brain/spinal fluid spread, recent major bleeding risk, or recent investigational drug/device use)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests a new combination of drugs (SYS6010, enlonstobart, and chemotherapy) as a first treatment for people with advanced esophageal cancer that has not spread elsewhere. It aims to find a more effective option for patients who have not received prior therapy for their advanced disease.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.